MX378640B - Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina. - Google Patents
Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina.Info
- Publication number
- MX378640B MX378640B MX2019003468A MX2019003468A MX378640B MX 378640 B MX378640 B MX 378640B MX 2019003468 A MX2019003468 A MX 2019003468A MX 2019003468 A MX2019003468 A MX 2019003468A MX 378640 B MX378640 B MX 378640B
- Authority
- MX
- Mexico
- Prior art keywords
- thieno
- protein kinase
- inhibitory activity
- pyrimidine derivatives
- kinase inhibitory
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Abstract
Se proporcionan derivados de tieno[3,2-d]pirimidina de la fórmula (I) o las sales aceptables farmacéuticamente de los mismos que tienen actividad inhibidora para las cinasas de proteína y composiciones farmacéuticas que comprenden los mismos para la prevención y el tratamiento de las enfermedades de crecimiento anormal de las células.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110146818 | 2011-12-30 | ||
| PCT/KR2012/011571 WO2013100632A1 (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003468A MX2019003468A (es) | 2019-06-06 |
| MX378640B true MX378640B (es) | 2025-03-10 |
Family
ID=48697978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003468A MX378640B (es) | 2011-12-30 | 2012-12-27 | Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina. |
| MX2014007230A MX363659B (es) | 2011-12-30 | 2012-12-27 | Derivados de tieno [3, 2 - d] pirimidina que tienen actividad inhibidora de las cinasas de proteína. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007230A MX363659B (es) | 2011-12-30 | 2012-12-27 | Derivados de tieno [3, 2 - d] pirimidina que tienen actividad inhibidora de las cinasas de proteína. |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9156852B2 (es) |
| EP (2) | EP3617213B1 (es) |
| JP (1) | JP5797345B2 (es) |
| KR (1) | KR101490761B1 (es) |
| CN (1) | CN104039798B (es) |
| AR (1) | AR089489A1 (es) |
| AU (1) | AU2012363558C1 (es) |
| BR (2) | BR112014015720B1 (es) |
| CA (1) | CA2859668C (es) |
| CL (1) | CL2014001729A1 (es) |
| CO (1) | CO7010840A2 (es) |
| DK (1) | DK2797927T3 (es) |
| ES (2) | ES3013322T3 (es) |
| HR (1) | HRP20191840T8 (es) |
| HU (1) | HUE045957T2 (es) |
| IL (2) | IL233441B (es) |
| IN (1) | IN2014DN06101A (es) |
| LT (1) | LT2797927T (es) |
| MX (2) | MX378640B (es) |
| MY (1) | MY170988A (es) |
| PE (1) | PE20141404A1 (es) |
| PH (1) | PH12014501504B1 (es) |
| PL (1) | PL2797927T3 (es) |
| PT (1) | PT2797927T (es) |
| RS (1) | RS59420B1 (es) |
| RU (2) | RU2705577C2 (es) |
| SG (2) | SG11201402765TA (es) |
| SI (1) | SI2797927T1 (es) |
| TW (1) | TWI462927B (es) |
| UA (1) | UA109614C2 (es) |
| WO (1) | WO2013100632A1 (es) |
| ZA (1) | ZA201405583B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| EP3207023B1 (en) | 2014-10-14 | 2019-09-18 | Syngenta Participations AG | Process for the preparation of 1-(3,5-dichlorophenyl)-2,2,2-trifluoroethanone and derivatives thereof |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| SG11201803242TA (en) | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
| KR20180070696A (ko) | 2015-10-29 | 2018-06-26 | 이펙터 테라퓨틱스, 인크. | Mnk1 및 mnk2를 억제하는 피롤로-, 피라졸로-, 이미다조-피리미딘 및 피리딘 화합물 |
| WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| CN106928252B (zh) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其制备方法与应用 |
| EP3414247B1 (en) * | 2016-02-08 | 2021-04-21 | F. Hoffmann-La Roche AG | Spiroindolinones as ddr1 inhibitors |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| CN106153920B (zh) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| PT3562821T (pt) * | 2016-12-28 | 2021-03-03 | Minoryx Therapeutics S L | Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018152117A1 (en) | 2017-02-14 | 2018-08-23 | Effector Therapeutics, Inc. | Piperidine-substituted mnk inhibitors and methods related thereto |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| MX393995B (es) | 2017-07-28 | 2025-03-24 | Yuhan Corp | Proceso mejorado para preparar derivados de aminopirimidina |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| MX2020005564A (es) * | 2017-11-30 | 2020-11-06 | Hanmi Pharm Ind Co Ltd | Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas. |
| IL274963B2 (en) * | 2017-11-30 | 2024-10-01 | Hanmi Pharmaceutical Co Ltd | THIENO[3,2-d]PYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| US11130757B2 (en) | 2018-10-24 | 2021-09-28 | Effector Therapeutics Inc. | Crystalline forms of MNK inhibitors |
| KR102921276B1 (ko) | 2018-11-21 | 2026-02-03 | 케이스 웨스턴 리저브 유니버시티 | 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법 |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN110183464B (zh) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | 一种抗癌化合物艾斯替尼及其合成方法和应用 |
| JP2023531375A (ja) * | 2020-05-26 | 2023-07-24 | ハンミ ファーム．カンパニー リミテッド | がん治療における使用のためのベルバラフェニブ |
| US12577240B2 (en) | 2020-07-11 | 2026-03-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| KR20230096965A (ko) * | 2020-10-27 | 2023-06-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 아릴아미드 화합물, 이를 포함하는 약학적 조성물, 및 이의 제조방법 및 용도 |
| US20240002394A1 (en) * | 2020-11-24 | 2024-01-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Deuterium-modified thienopyridone compound |
| US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| US20240366609A1 (en) | 2021-04-06 | 2024-11-07 | Genentech, Inc. | Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab |
| US20240239895A1 (en) | 2021-04-09 | 2024-07-18 | Genentech, Inc. | Combination therapy with a raf inhibitor and a pd-1 axis inhibitor |
| CA3225147A1 (en) | 2021-06-30 | 2023-01-05 | Genentech, Inc. | Synthesis of a bis-mesylate salt of 4-amino-n-(1 -((3-chloro-2- fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide and intermediates thereto |
| CN114213430B (zh) * | 2021-12-28 | 2022-12-02 | 深圳湾实验室 | 4-氨基噻吩[3,2-d]嘧啶-7-羧酸的制备方法、蛋白激酶抑制剂中间体 |
| CN114524826A (zh) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺 |
| CN119156457A (zh) | 2022-03-02 | 2024-12-17 | 诺华有限公司 | 用于癌症治疗的精准疗法 |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402518D0 (en) * | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| RU2556984C2 (ru) * | 2004-06-24 | 2015-07-20 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CN101563336A (zh) * | 2006-03-16 | 2009-10-21 | 诺瓦提斯公司 | 用于治疗特别是黑素瘤的杂环有机化合物 |
| CN101466716A (zh) | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| MY155535A (en) | 2008-05-23 | 2015-10-30 | Novartis Ag | Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors |
| CA2744713A1 (en) * | 2008-12-05 | 2010-06-10 | Arqule, Inc. | Raf inhibitors and their uses |
| WO2010101302A1 (en) * | 2009-03-05 | 2010-09-10 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
| DE102009035754A1 (de) | 2009-07-24 | 2011-01-27 | Hartmetall-Werkzeugfabrik Paul Horn Gmbh | Schneideinsatz für ein Schneidwerkzeug zur spanenden Bearbeitung, insbesondere zum Hochvorschubfräsen |
| CN102712646A (zh) | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| KR101147550B1 (ko) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| KR101094446B1 (ko) * | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| CA2786438C (en) * | 2010-01-29 | 2015-10-13 | Hanmi Science Co., Ltd. | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
| KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| KR101995013B1 (ko) * | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
-
2012
- 2012-12-27 RS RSP20191305 patent/RS59420B1/sr unknown
- 2012-12-27 PT PT128618113T patent/PT2797927T/pt unknown
- 2012-12-27 JP JP2014550010A patent/JP5797345B2/ja active Active
- 2012-12-27 HU HUE12861811A patent/HUE045957T2/hu unknown
- 2012-12-27 CA CA2859668A patent/CA2859668C/en active Active
- 2012-12-27 MY MYPI2014701742A patent/MY170988A/en unknown
- 2012-12-27 SI SI201231684T patent/SI2797927T1/sl unknown
- 2012-12-27 ES ES19198802T patent/ES3013322T3/es active Active
- 2012-12-27 LT LT12861811T patent/LT2797927T/lt unknown
- 2012-12-27 AR ARP120105010A patent/AR089489A1/es active IP Right Grant
- 2012-12-27 DK DK12861811T patent/DK2797927T3/da active
- 2012-12-27 IN IN6101DEN2014 patent/IN2014DN06101A/en unknown
- 2012-12-27 SG SG11201402765TA patent/SG11201402765TA/en unknown
- 2012-12-27 HR HRP20191840TT patent/HRP20191840T8/hr unknown
- 2012-12-27 ES ES12861811T patent/ES2751608T3/es active Active
- 2012-12-27 PL PL12861811T patent/PL2797927T3/pl unknown
- 2012-12-27 CN CN201280064739.8A patent/CN104039798B/zh active Active
- 2012-12-27 US US14/363,857 patent/US9156852B2/en not_active Ceased
- 2012-12-27 EP EP19198802.1A patent/EP3617213B1/en active Active
- 2012-12-27 KR KR20120154061A patent/KR101490761B1/ko active Active
- 2012-12-27 US US15/783,240 patent/USRE47451E1/en active Active
- 2012-12-27 WO PCT/KR2012/011571 patent/WO2013100632A1/en not_active Ceased
- 2012-12-27 PE PE2014001048A patent/PE20141404A1/es active IP Right Grant
- 2012-12-27 BR BR112014015720-0A patent/BR112014015720B1/pt active IP Right Grant
- 2012-12-27 AU AU2012363558A patent/AU2012363558C1/en active Active
- 2012-12-27 EP EP12861811.3A patent/EP2797927B1/en active Active
- 2012-12-27 RU RU2017124993A patent/RU2705577C2/ru active
- 2012-12-27 RU RU2014131390A patent/RU2625799C2/ru active
- 2012-12-27 BR BR122019019582-0A patent/BR122019019582B1/pt active IP Right Grant
- 2012-12-27 SG SG10201701999QA patent/SG10201701999QA/en unknown
- 2012-12-27 UA UAA201408629A patent/UA109614C2/ru unknown
- 2012-12-27 MX MX2019003468A patent/MX378640B/es unknown
- 2012-12-27 MX MX2014007230A patent/MX363659B/es unknown
- 2012-12-28 TW TW101151181A patent/TWI462927B/zh active
-
2014
- 2014-06-26 CL CL2014001729A patent/CL2014001729A1/es unknown
- 2014-06-27 PH PH12014501504A patent/PH12014501504B1/en unknown
- 2014-06-29 IL IL233441A patent/IL233441B/en active IP Right Grant
- 2014-07-25 CO CO14162082A patent/CO7010840A2/es active IP Right Grant
- 2014-07-29 ZA ZA2014/05583A patent/ZA201405583B/en unknown
-
2019
- 2019-04-28 IL IL266285A patent/IL266285B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378640B (es) | Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina. | |
| WO2011093684A3 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | |
| TR201906936T4 (tr) | Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri. | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| HK1199725A1 (en) | Heterocyclic compounds and uses thereof | |
| HK1198443A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| SG11201408052WA (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| HK1207069A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| EA201390347A1 (ru) | Лечение заболеваний | |
| BR112016015235A2 (pt) | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento | |
| UA113215C2 (xx) | Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду | |
| WO2012030160A3 (en) | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | |
| MX341728B (es) | Derivados sulfonamido de 3, 4/diarilpirazoles como inhibidores de proteina quinasa. | |
| HK1249408A1 (zh) | 治疗葡萄膜黑素瘤的mdm2抑制剂 | |
| IN2012DN06061A (es) | ||
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| AU2012225365A8 (en) | Peptide deformylase inhibitors | |
| WO2011090317A3 (en) | Imidazopyrazinone derivatives with apoptosis inducing activity on cells | |
| MY187891A (en) | Tetrahydropyridine derivatives as fabi inhibitors |